Werewolf Therapeutics (NASDAQ:HOWL) Downgraded by Wedbush to Neutral

Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by equities researchers at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued to investors on Friday. They currently have a $1.00 price target on the stock. Wedbush’s price target indicates a potential upside of 41.84% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Bank of America decreased their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. JMP Securities lowered their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.75.

Werewolf Therapeutics Stock Up 9.0%

Shares of Werewolf Therapeutics stock traded up $0.06 on Friday, hitting $0.71. 367,903 shares of the company’s stock traded hands, compared to its average volume of 523,602. Werewolf Therapeutics has a 52-week low of $0.56 and a 52-week high of $2.38. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The stock has a market cap of $34.22 million, a P/E ratio of -0.44 and a beta of 0.74. The firm’s 50-day moving average is $1.20 and its 200 day moving average is $1.32.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Equities analysts anticipate that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Insider Transactions at Werewolf Therapeutics

In related news, major shareholder Bioventures 2014 L.P. Mpm sold 83,230 shares of Werewolf Therapeutics stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $0.97, for a total value of $80,733.10. Following the transaction, the insider directly owned 4,784,111 shares in the company, valued at $4,640,587.67. The trade was a 1.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Ansbert Gadicke sold 83,230 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $0.97, for a total value of $80,733.10. Following the sale, the insider directly owned 4,784,111 shares of the company’s stock, valued at approximately $4,640,587.67. This represents a 1.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,337,021 shares of company stock valued at $6,108,970 in the last three months. 23.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP grew its position in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares in the last quarter. MPM Bioimpact LLC boosted its position in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Werewolf Therapeutics by 33.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after buying an additional 23,852 shares in the last quarter. MPM Asset Management LLC raised its position in Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after buying an additional 25,688 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth about $28,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.